Previous pregnancy outcomes of aPL-positive patients. Values are n (%) unless otherwise specified.
| Outcomes | All aPL, n = 47/55 | aPS/PT+, n = 30 | aPS/PT−, n = 17 | p* |
|---|---|---|---|---|
| ≥ 1 pregnancy loss < 10 wg | 20 | 10 (33) | 10 (59) | NS |
| RPL < 10 wg† | 7 | 2 (7) | 5 (29) | NS |
| ≥ 1 pregnancy loss > 10 wg | 18 | 12 (40) | 6 (35) | NS |
| IFD | 13 | 11 (37) | 2 (12) | NS |
| IUGR | 20 | 16 (53) | 4 (24) | 0.04 |
| Preeclampsia | 8 | 6 (20) | 2 (12) | NS |
↵* Statistically different from aPS/PT−, patients.
↵† Miscarriages, defined as ≥ 2 pregnancy loss. Values in bold face are statistically significant. aPL: antiphospholipid antibodies; aPS/PT: antiphosphatidylserine/prothrombin antibodies; SLE: systemic lupus erythematosus; UCTD: undifferentiated connective tissue disease; LLAC: lupus-like anticoagulant; anti-β2-GPI: anti-β2 glycoprotein I antibodies; IgG: immunoglobulin G; aCL: anticardiolipin antibodies; RPL: recurrent pregnancy loss; IFD: intrauterine fetal death; IUGR: intrauterine growth restriction; NS: not significant.